rituximab sold brand name rituxan among others monoclonal antibody medication used treat certain autoimmune diseases types used nonhodgkin lymphoma chronic lymphocytic leukemia nongeriatric patients rheumatoid arthritis granulomatosis polyangiitis idiopathic thrombocytopenic purpura pemphigus vulgaris myasthenia gravis viruspositive mucocutaneous given slow intravenous infusion injected slowly iv biosimilars rituxan include blitzima riabni ritemvia rituenza fka tuxella rixathon ruxience common side effects often occur within two hours medication given include rash itchiness low blood pressure shortness breath infections also severe side effects include reactivation hepatitis b previously infected progressive multifocal leukoencephalopathy toxic epidermal necrolysis unclear use pregnancy safe developing fetus newborn proven harmful rituximab chimeric monoclonal antibody protein primarily found surface immune system b binds protein triggers cell rituximab approved medical use world health organizations list essential rituximab comarketed biogen genentech us hoffmannla roche canada european union chugai pharmaceuticals zenyaku kogyo japan aryogen rituximab chimeric monoclonal antibody targeted surface antigen present b cells therefore acts depleting normal well pathogenic b cells sparing plasma cells hematopoietic stem cells express surface united states rituximab indicated treat rituximab used treat cancers white blood system leukemias lymphomas including nonhodgkins lymphoma chronic lymphocytic leukemia nodular lymphocyte predominant hodgkins also includes waldenströms macroglobulinemia type rituximab combination hyaluronidase human sold brand names mabthera sc rituxan used treat follicular lymphoma diffuse large bcell lymphoma chronic lymphocytic used combination fludarabine cyclophosphamide treat previously untreated previously treated chronic lymphocytic rituximab shown effective rheumatoid arthritis treatment three randomised controlled trials licensed use refractory rheumatoid united states fdaapproved use combination methotrexate mtx reducing signs symptoms adult patients moderately severely active rheumatoid arthritis ra inadequate response one antitnfalpha therapy european union license slightly restrictive licensed use combination mtx patients severe active ra inadequate response one antitnf evidence efficacy necessarily safety range autoimmune diseases rituximab widely used offlabel treat difficult cases multiple systemic lupus erythematosus chronic inflammatory demyelinating polyneuropathy autoimmune dangerous although among rare side effect progressive multifocal leukoencephalopathy pml infection usually fatal however small number cases recorded occurring autoimmune autoimmune diseases treated rituximab include autoimmune hemolytic anemia pure red cell aplasia thrombotic thrombocytopenic purpura idiopathic thrombocytopenic purpura evans vasculitis eg granulomatosis polyangiitis bullous skin disorders example pemphigus encouraging results approximately rapid recovery pemphigus according type diabetes mellitus sjögren syndrome antinmda receptor encephalitis devics disease mog antibody graves autoimmune opsoclonus myoclonus syndrome evidence ineffective treating igamediated autoimmune serious adverse events cause death disability two patients systemic lupus erythematosus died progressive multifocal leukoencephalopathy pml treated rituximab pml caused activation jc virus common virus brain usually latent reactivation jc virus usually results death severe brain least one patient rheumatoid arthritis developed pml treatment rituximab reported possible cofactor chronic hepatitis e infection person lymphoma hepatitis e infection normally acute infection suggesting drug combination lymphoma may weakened bodys immune response major concern continuous rituximab treatment difficulty induce proper vaccine brought focus pandemic persons multiple sclerosis rituximab treatment higher risk severe persons rituximab treatment multiple sclerosis patients b cell counts developed protective levels antibodies vaccination antibody binds cell surface protein widely expressed b cells early preb cells later differentiation absent terminally differentiated plasma cells although function unknown may play role influx across plasma membranes maintaining intracellular concentration allowing activation b cells rituximab relatively ineffective elimination cells low cellsurface tends stick one side b cells forming cap drawing proteins side presence cap changes effectiveness natural killer nk cells destroying b cells nk cell latched onto cap success rate killing cell contrast b cell lacked asymmetric protein cluster killed following effects combined effect results elimination b cells including cancerous ones body allowing new population healthy b cells develop lymphoid stem cells rituximab binds amino acids physically close result disulfide bond amino acids rituximab developed idec pharmaceuticals name us patent drug issued expired based safety effectiveness clinical rituximab approved us food drug administration treat bcell nonhodgkin lymphomas resistant chemotherapy rituximab combination chop chemotherapy superior chop alone treatment diffuse large bcell lymphoma many bcell approved european commission maintenance treatment initial treatment follicular world health organizations list essential genentech reclassified rituxan specialty drug class drugs available specialty distributors wholesalers discounts rebates longer apply hospitals would pay originally available intravenous injection eg hrs gained eu approval formulation subcutaneous injection bcell clllymphoma patents drug expired europe february us september november several biosimilars approved us india european union switzerland japan australia us fda approved truxima rituximababbs ruxience rituximabpvvr riabni rituximabarrx latter per mg wholesale rituximab improve symptoms patients chronic fatigue syndrome trial published participants serious potential use investigated improvements chronic fatigue syndrome seen two cancer patients treated cns diseases rituximab could administered intrathecally possibility efficacy success rituximab led monoclonal antibodies developed httpsenwikipediaorgwikirituximab